Literature DB >> 16723167

Efficient ex vivo gene transfer into non-human primate hepatocytes using HIV-1 derived lentiviral vectors.

Alexandre Parouchev1, Tuan Huy Nguyen, Ibrahim Dagher, Sylvie Mainot, Marie-Thérèse Groyer-Picard, Julie Branger, Patrick Gonin, James Di Santo, Dominique Franco, Gabriel Gras, Anne Weber.   

Abstract

BACKGROUND/AIMS: Lentivirus-mediated ex vivo gene therapy is becoming a promising approach for the treatment of liver metabolic disorders. However, the feasibility of this approach needs to be studied in large animal models. The purpose of this study was to evaluate the efficacy of ex vivo gene transfer into Macaca hepatocytes with two different HIV-1 derived lentiviral vectors.
METHODS: A self-inactivating lentivector was constructed to express GFP under the control of the hepatic apolipoprotein A-II promoter. Freshly isolated and thawed hepatocytes were transduced in suspension with lentiviral vectors expressing the GFP gene under the control of a ubiquitous promoter (EF1-alpha) and the apolipoprotein A-II promoter. Transduced thawed hepatocytes were transplanted into the spleen of newborn mice, and livers analyzed 4 and 12 weeks after transplantation.
RESULTS: We show that lentivectors are efficient in transducing hepatocytes in suspension either freshly isolated or cryopreserved. We also show that thawed and transduced hepatocytes engrafted and participated in liver growth after transplantation into newborn mice and that the apolipoprotein A-II promoter is functional.
CONCLUSIONS: Our data show that transplantation of transduced hepatocytes into monkeys should allow to evaluate the fate of transplanted cells and transgene expression in a pre-clinical model of ex vivo gene therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723167     DOI: 10.1016/j.jhep.2006.03.014

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  Biosafety in ex vivo gene therapy and conditional ablation of lentivirally transduced hepatocytes in nonhuman primates.

Authors:  Olivier Menzel; Jacques Birraux; Barbara E Wildhaber; Caty Jond; Françoise Lasne; Walid Habre; Didier Trono; Tuan H Nguyen; Christophe Chardot
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

2.  Hepatocyte transplantation: studies in preclinical models.

Authors:  Anne Weber; Dominique Mahieu-Caputo; Michelle Hadchouel; Dominique Franco
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

3.  Ex vivo gene delivery to hepatocytes: techniques, challenges, and underlying mechanisms.

Authors:  Shan Gao; Erkin Seker; Monica Casali; Fangjing Wang; Shyam Sundhar Bale; Gavrielle M Price; Martin L Yarmush
Journal:  Ann Biomed Eng       Date:  2012-04-07       Impact factor: 3.934

4.  Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.

Authors:  Caitlin VanLith; Rebekah Guthman; Clara T Nicolas; Kari Allen; Zeji Du; Dong Jin Joo; Scott L Nyberg; Joseph B Lillegard; Raymond D Hickey
Journal:  Hum Gene Ther       Date:  2018-06-22       Impact factor: 5.695

5.  Short term but highly efficient Cas9 expression mediated by excisional system using adenovirus vector and Cre.

Authors:  Sayaka Nagamoto; Miyuki Agawa; Emi Tsuchitani; Kazunori Akimoto; Saki Kondo Matsushima; Yumi Kanegae
Journal:  Sci Rep       Date:  2021-12-21       Impact factor: 4.379

6.  Integration-deficient lentivectors: an effective strategy to purify and differentiate human embryonic stem cell-derived hepatic progenitors.

Authors:  Guanghua Yang; Karim Si-Tayeb; Sébastien Corbineau; Rémi Vernet; Régis Gayon; Noushin Dianat; Clémence Martinet; Denis Clay; Sylvie Goulinet-Mainot; Gérard Tachdjian; Gérard Tachdjian; Deborah Burks; Ludovic Vallier; Pascale Bouillé; Anne Dubart-Kupperschmitt; Anne Weber
Journal:  BMC Biol       Date:  2013-07-19       Impact factor: 7.431

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.